Introduction {#Sec1}
============

The severe form of acute pancreatitis (SAP), defined as single or multiple persistent organ failure (OF) by Revised Atlanta Classification (RAC), carries a mortality of 36--50% \[[@CR1]\]. The most common OF is respiratory dysfunction and failure \[[@CR2], [@CR3]\]. Despite many advances in our understanding of the pathophysiology of AP, there remains no effective pharmacological treatment \[[@CR4]\]. Fluid resuscitation is considered the cornerstone of early treatment of AP \[[@CR5], [@CR6]\], although there are many unanswered questions regarding the type of fluid to use, how fast to give it, and how best to monitor the response to it \[[@CR7]\].

A number of studies have investigated the rate of fluid administration in patients with AP. Many clinicians advocate \[[@CR5], [@CR6]\] "early aggressive" fluid therapy on the basis that this reduces the systemic inflammatory response syndrome (SIRS), incidence of OF and hospital length of stay (LOS), but the benefits were more pronounced for mild than severe cases \[[@CR8]\]. Other studies have suggested that in patients with predominately mild AP, early aggressive fluid therapy is associated with reduced LOS \[[@CR9], [@CR10]\] and improved composite clinical outcomes \[[@CR11]\]. In contrast, clinicians advocating a more moderate approach to fluid resuscitation argue that pancreatic necrosis is irreversible and that a higher volume of fluid given over the first 24 h is associated with higher incidence of respiratory dysfunction/failure, local complications, sepsis, and mortality \[[@CR3], [@CR12]--[@CR14]\]. A randomized controlled clinical trial of patients with predicted SAP had a significantly worse clinical outcome with rapid fluid expansion \[[@CR15], [@CR16]\]. The International Association of Pancreatology (IAP)/American Pancreatic Association (APA) \[[@CR6]\], American College of Gastroenterology (ACG) \[[@CR5]\], and Japanese Practice Guidelines \[[@CR17]\] all recommend aggressive hydration although at different fluid rates (Table [1](#Tab1){ref-type="table"}). Given the conflicting low level evidence, the American Gastroenterology Association (AGA) Practice Guidelines \[[@CR18]\] only recommend "early goal-directed" fluid therapy without providing details for other important aspects of fluid therapy. While there is some evidence that early goal-directed therapy decreases mortality in severe sepsis and septic shock \[[@CR19]\], subsequent trials have not confirmed this (i.e., ARISE, PROCESS, and PROMISE) \[[@CR20]--[@CR22]\]. Many other goals have been proposed \[[@CR23]\] and while the goal-directed approach is an attractive concept, none have been adequately validated in the management of patients with AP. In the absence of a proven goal for fluid resuscitation, it is not yet possible to recommend a goal-directed approach in AP patients.Table 1Summary of clinical guidelines of aggressive hydration in acute pancreatitisGuidelinesFluid rate2013 IAP and APAGoal-directed intravenous fluid therapy with 5--10 ml/kg/h2013 ACGAggressive hydration, defined as 250--500 ml/h crystalloid solution2015 Japanese guidelineShort-time rapid fluid resuscitation (150--600 ml/h) depending on the presence of shock and the dehydration level2018 AGAGoal-directed therapy for fluid management2019 WSESFluid overload is known to have detrimental effects, and early fluid resuscitation should be guided by frequent reassessment of the hemodynamic status*IAP* International Association of Pancreatology,*APA* American Pancreatic Association,*ACG* American College of Gastroenterology,*AGA* American Gastroenterology Association,*WSES* World Society of Emergency Surgery

The most commonly used goals of fluid resuscitation are the normalization of urine output and blood pressure \[[@CR23]\], but this has been shown to risk fluid overload and increased mortality \[[@CR24]\]. The laboratory marker that shows promise as a goal and a guide to fluid therapy in patients with AP is hematocrit \[[@CR25]\]. Hematocrit is the volume percentage of red blood cells in blood, or a marker of hemoconcentration or hemodilution. Hemoconcentration in AP was first described in the 1960s \[[@CR26]\]. In 1998, Baillargeon et al. \[[@CR27]\] reported that an admission serum hematocrit level ≥ 47% that did not decrease during the first 24 h was predictive of acute necrotic collection (ANC). Subsequent prospective studies \[[@CR28]--[@CR30]\] by the same group suggested that an admission hematocrit level ≥ 44%, especially if it increased at 24 h, was a significant predictor for both ANC and OF. This has been confirmed in a recent study of 1,612 AP patients, where admission hematocrit \> 44% was a more accurate predictor of ANC and persistent OF than other biomarkers \[[@CR31]\]. A randomized controlled clinical trial of patients with predicted SAP had a significantly worse clinical outcome when hematocrit was decreased to \< 35% within 48 h of commencing fluid resuscitation, i.e., rapid hemodilution \[[@CR15], [@CR16]\]. The IAP/APA Practice Guidelines recommend that the goal of fluid therapy should be to maintain hematocrit levels at 35--44% \[[@CR6]\].

In this study, we undertook retrospective analysis of prospectively collected data from the largest AP tertiary center in China (Supplementary Fig. S1) to determine the relationship between early rapid fluid therapy (ERFT), hemoconcentration, and clinical outcomes in patients with AP after general ward admission. The hypothesis was that ERFT is associated with increased risk of respiratory dysfunction requiring noninvasive positive-pressure ventilation (NPPV) in hemoconcentrated SAP patients.

Materials and Methods {#Sec2}
=====================

Study Design and Setting {#Sec3}
------------------------

A retrospective analysis was conducting using the STROBE guidelines \[[@CR32]\] of the AP database at West China Hospital of Sichuan University. This is the largest center in China managing patients with AP. The study protocol was approved by the Institutional Review Board (No. 247) of the hospital, and informed consent was waived. Data from consecutive AP patients admitted to the Pancreatitis Center between January 1, 2016, and August 31, 2017, were prospectively collected into our database (Microsoft Access, Redmond, USA) by data managers using electronic Heath Information System (Donghua Medical, Shenzhen, China). Data regarding fluid therapy were retrospectively collected using International Classification of Diseases 10th edition (ICD-10) code K85 for patient identification.

Data Collection {#Sec4}
---------------

Quality assurance, quality control, standard operating procedures, and researcher training were implemented in the study process. Retrospective data collection for fluid collection was undertaken by two experienced clinical researchers (LL and TJ) using a pre-defined *pro forma* designed by senior authors (QX and WH) and audited by clinical leads (LD, KJ, and ZL).

Inclusion and Exclusion Criteria {#Sec5}
--------------------------------

AP was diagnosed by two of three criteria: epigastric abdominal pain, elevated amylase or lipase \> 3 times of the upper limit of normal, and/or imaging consistent with AP \[[@CR1]\]. Confirmed AP patients who had symptom onset ≤ 48 h when admitted to general wards were included regardless of the disease episodes. Exclusion criteria included those in whom AP was not the primary admitting diagnosis; ages \< 18 or \> 70 years; patients transferred to ICU admission within 24 h of ward admission; AP due to trauma or pancreatic cancer; chronic pancreatitis; pregnancy; advanced comorbidities; incomplete data for extraction (for example, lack of body weight, height, or computed tomography images).

Fluid and Intensive Care Management {#Sec6}
-----------------------------------

In the West China Hospital, AP patients are initially admitted to the Emergency Department (ED). After confirming the diagnosis and initiation of fluid therapy with normal saline in the ED, patients are transferred to a general ward. Once transferred to the ward, patients have continuation of fluid therapy with (normal saline or Ringer's lactate solution) at 1--5 ml/kg/h for the first 24 h, with the rate based on predicted severity of AP and the clinical assessment of hydration status, rather than based on a pre-defined resuscitation protocol. Patients do not routinely receive additional fluid as a bolus (e.g., 10--20 ml/kg/h over 30--45 min) unless they were shocked, with mean arterial pressure \< 65 mm Hg \[[@CR33]\]. Patients are admitted to a ward-based high-dependency unit (HDU) if they meet the criteria for NPPV \[[@CR34]\]. Indications for NPPV are: patients alert and orientated, able to control airway and clear secretion but experiencing tachypnea (respiratory rate \> 25/min) or dyspnea (use of accessory muscles for breathing), or arterial partial pressure of PaO~2~ \< 60 mm Hg, with or without partial pressure of CO~2~ \> 45 mm Hg (measured by Roche Cobas b123 automatic blood gas analyzer; Shanghai, China), despite high flow oxygen by humidified non-rebreather mask (1060, Teleflex Medical; Limerick, PA, USA) at 8 L/min. The NPPV is delivered by Respironics V60 in the BiPAP S/T mode (Philips Respironics, BiPAP^®^ Vision™; Pittsburgh, PA, USA) with a positive end expiratory pressure of 4--6 cmH~2~O. Patients are admitted to intensive care unit (ICU) for mechanical ventilation, renal replacement therapy, and/or the need for continuous vasopressors/inotropes.

Study Definitions {#Sec7}
-----------------

### *"Severity" of AP* {#FPar1}

The actual severity of AP patients was used to stratify patients, using the RAC criteria \[mild AP (MAP), moderately severe AP (MSAP), and SAP\] based on the most severe grade during period of index hospital admission \[[@CR1]\].

### *"Early" fluid therapy* {#FPar2}

This was the "first 6 h" of fluid therapy administered on the general wards, after transfer from ED. This did not include the fluid administered in the ED prior to transfer.

### *"Rate" of fluid therapy* {#FPar3}

The rate of fluid infusion was defined as "rapid" if it was ≥ 3 ml/kg/h (with "slow" \< 3 ml/kg/h), based on the average rate of fluid therapy during the first 6 h of admission on general ward. Thus, ERFT would be ≥ 225 ml/h for a 75-kg person over the first 6 h and "early slow fluid therapy" (ESFT) \< 225 ml/h. The cut-off fluid rate of 3 ml/kg/h was taken from ACG Guidelines (≥ 250 ml/h) \[[@CR5]\].

### *Hemoconcentration* {#FPar4}

Hematocrit was also measured at the time of admission to the general ward and not admission to ED. Hemoconcentration was defined as serum hematocrit \> 44% \[[@CR27], [@CR28], [@CR31]\].

Patients Groups {#Sec8}
---------------

The patients were stratified into 4 groups based on hematocrit and fluid rate and all in reference to the first 6 h of admission to the general wards:**Group A** hematocrit ≤ 44% on admission and fluid rate \< 3 ml/kg/h,**Group B** hematocrit ≤ 44% on admission and fluid rate ≥ 3 ml/kg/h,**Group C** hematocrit \> 44% on admission and fluid rate \< 3 ml/kg/h,**Group D** hematocrit \> 44% on admission and fluid rate ≥ 3 ml/kg/h.

Outcomes {#Sec9}
--------

The primary clinical outcome measure was the rate of NPPV. We have selected NPPV as the primary endpoint because respiratory dysfunction/failure is the most common organ system affected, and because we have demonstrated that the most frequently noted consequence of ERFT is respiratory dysfunction \[[@CR24]\]. In our setting, NPPV is the most commonly used means of organ support and it is frequently used in the general ward setting, and has been shown to reduce the need for ICU admission and invasive ventilation \[[@CR34]\]. Secondary outcomes included persistent OF, multiple OF (MOF), HDU admission, ICU admission, local pancreatic complications, drainage necrosectomy, overall mortality, length of overall hospital stay (LOS), and costs. Definitions for etiologies and other study variables are shown in Supplementary Methods.

Statistical Analysis {#Sec10}
--------------------

Baseline parameters and clinical outcomes were compared between groups A and B (non-hemoconcentrated: ESFT vs. ERFT) or groups C and D (hemoconcentrated: ESFT vs. ERFT). Groups A and C (ESFT: non-hemoconcentrated vs. hemoconcentrated) were also compared with groups B and D (ERFT: non-hemoconcentrated vs. hemoconcentrated). Categorical data are expressed as number and percentage and compared by $\documentclass[12pt]{minimal}
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                \begin{document}$$\chi^{2}$$\end{document}$ test (or Fisher's exact test). Continuous data are presented as median and interquartile range (IQR) and compared using Mann--Whitney *U* test (2 groups) or Kruskal--Wallis *H* test (3 groups) if distribution was skewed. Baseline variables with or without clinical severity score on ward admission were compared between groups using univariate analysis. Those covariates with *P* value \< 0.2 were further fitted into: (1) multivariate logistic regression analyses for categorical clinical outcomes and linear regression analyses for qualitative clinical outcomes and LOS of MAP and MSAP \[[@CR1]\], respectively, and expressed as odds ratio (OR) with 95% confidence interval (CI); or (2) Cox regression analyses for predicted hospital discharge and expressed as hazard ratios (HR) with 95% CI. In the Cox analysis, days for deceased patients are considered as truncated data. A two-sided *P *\< 0.05 was considered statistically significant. Statistical analyses were performed using SPSS^®^ 21.0 (IBM, Armonk, New York, USA).

Results {#Sec11}
=======

Characteristics of Patient Cohort {#Sec12}
---------------------------------

The algorithm for fluid therapy and patient selection is presented in Fig. [1](#Fig1){ref-type="fig"}. A total of 912 patients were included in the study. The baseline characteristics and clinical outcomes stratified by RAC severity grades \[[@CR1]\] are summarized in Table [2](#Tab2){ref-type="table"}: 352 (38.6%) were MAP, 412 (45.2%) MSAP, and 148 (16.2%) SAP. The median age was 45 years (range 19 to 70 years), and 68% were males. Hypertriglyceridemia (36.7%) was the leading etiology, followed by biliary (23.1%) and alcohol (7.8%), consistent with our recent findings from large cohorts \[[@CR2], [@CR35], [@CR36]\]. The median time from symptom onset to general ward admission was 24 h (range 6--48 h), and that from ED to general ward was 6.5 h (range 4--19.5 h). Of 148 patients with persistent OF, 95 (64%) had an onset ≤ 24 h of admission, followed by 44 (29.7%), 3 (2%) and 6 (4%) on day 1, 2, and 3 and days ≥ 4, respectively (Supplementary Fig. 2). There were 145 \[15.9%\] respiratory, 10 \[1.0%\] circulatory, and 22 \[2.4%\] renal persistent OF with 22 (2.4%) had MOF. There were 157 (17.2%) admitted to HDU/ICU. Local pancreatic complications were diagnosed in a total of 518 patients: 331 (46.5%) had acute peripancreatic fluid collections (APFC), and 187 (20.5%) had ANC. Pancreatic necrosectomy was performed in 43 (6.0%) patients. All 27 patients who died had SAP (27/148, 18.2%), giving an overall mortality rate of 3.8% (Table [2](#Tab2){ref-type="table"}).Fig. 1Fluid therapy and patient selection process of acute pancreatitis. Patients selection process of the study. *AP* acute pancreatitis, *MAP* mild acute pancreatitis, *MSAP* moderate severe acute pancreatitis, *SAP* severe acute pancreatitis. \*Initial fluid therapyTable 2Baseline characteristics and clinical outcomes of overall included patientsParametersTotal (*n* = 912)MAP (*n* = 352)MSAP (*n* = 412)SAP (*n* = 148)*P* value^a^*Demographics*Age, years, median (IQR)45 (38--51)44 (39--51)45 (38--51)46 (41--52)0.004^b^Gender, male (%)620 (68.0)234 (66.7)285 (69.2)101 (68.2)0.437Body mass index, kg/m^2^ median (IQR)25.3 (23.0--27.7)25.3 (22.9--27.7)24.9 (22.8--27.3)26.3 (24.0--28.4)\< 0.001^b^Charlson comorbidity index, median (IQR)1 (0--2)2 (0--2)1 (0--2)1 (0--2)0.593Etiology Biliary211 (23.1)63 (17.9)112 (27.2)36 (24.3)0.002^c^ Hypertriglyceridemia335 (36.7)134 (38.2)140 (34.0)61 (41.2)0.229 Alcoholics71 (7.8)31 (8.9)26 (6.3)14 (9.5)0.241 Others295 (32.3)124 (35.2)134 (32.5)37 (25.0)0.205*Clinical scoring systems*SIRS, median (IQR)2 (1--2)1 (1--2)2 (1--2)3 (2--3)0.009^d^Glasgow, median (IQR)1 (0--2)1 (0--1)1 (0--2)2 (2--3)\< 0.001^d^APACHE II, median (IQR)4 (2--6)3 (2--5)4 (2--6)7 (5--10)\< 0.001^d^SOFA, median (IQR)0 (0--1)0 (0--0)0 (0--1)2 (0--3)\< 0.001^d^*Clinical outcomes*Single persistent OF Respiratory (%)145 (15.9)00145 (98.0)\< 0.001^d^ Circulatory (%)10 (1.0)0010 (6.8)\< 0.001^b^ Renal (%)22 (2.4)0022 (14.9)\< 0.001^b^MOF (%)22 (2.4)0022 (14.9)\< 0.001^b^HDU/ICU admission (%)157 (17.2)035 (8.5)122 (82.4)\< 0.001^d^Respiratory support (%)133 (18.7)010 (2.4)122 (82.4)0.013^d^Local complication Acute peripancreatic fluid collection (%)331 (46.5)0234 (56.8)97 (65.5)\< 0.001^d^ ANC (%)187 (20.5)0128 (31.3)59 (39.9)\< 0.001^d^Necrosectomy (%)43 (6.0)020 (4.9)23 (15.5)0.017^d^Mortality (%)27 (3.8)0027 (18.2)\< 0.001^b^Hospital LOS, median (IQR)^e^10 (7--14)8 (6--10)10 (7--14)17 (13, 24)\< 0.001^d^*MAP* mild acute pancreatitis, *MSAP* moderately severe acute pancreatitis, *SAP* severe acute pancreatitis, *IQR* interquartile range, *SIRS* systemic inflammatory response syndrome, *APACHE II* Acute Physiology and Chronic Health Evaluation II, *SOFA* Sequential Organ Failure Assessment, *OF* organ failure, *MOF* multiple organ failure, *HDU* high-dependency unit, *ICU* intensive care unit, *ANC* acute necrotic collection, *LOS* length of stay^a^Indicates *χ*^2^ (or Fisher's exact test) for qualitative data and Kruskal--Wallis *H* test for quantitative data^b^*P* \< 0.05, severe versus mild or moderate^c^*P* \< 0.05, mild versus moderate^d^*P* \< 0.05, between any two groups^e^Data from deceased patients are removed from the analysis

Baseline Parameters and Clinical Outcomes {#Sec13}
-----------------------------------------

Patients with hemoconcentration on admission (*n *= 313), compared with those without hemoconcentration (*n *= 599; Supplementary Table 1), were significantly younger (median 43 vs. 46 years, *P* \<0.001), more likely to be male (86.6% vs. 58.2%, *P* \<0.001), and had increased body mass index (26 vs. 24.7 kg/m^2^, *P* \< 0.001), Charlson comorbidity index (median score 2 vs. 1, *P* \< 0.05), and were associated with more severe clinical severity scores (SIRS, Glasgow, Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores; all *P* \< 0.001). In regard to clinical outcomes, the incidence of APFC, rate of necrosectomy, and LOS were similar between those with and without hemoconcentration. All other clinical outcomes of interest were significantly worse in the hemoconcentrated patients (Supplementary Table 2), including single persistent OF, MOF, ICU admission, respiratory support, ANC, and mortality.

Clinical Outcomes of Hemoconcentrated Patients Between Different Fluid Rates {#Sec14}
----------------------------------------------------------------------------

Furthermore, there was no difference in hospital LOS in MAP (Supplementary Table 3a); there were no differences all clinical outcomes of interest in MSAP (Supplementary Table 3b). In SAP patients, there was no difference in baseline parameters (including age, gender, body mass index, Charlson comorbidity index, time to admission, etiology, and admission clinical severity scoring system) and severity of acute respiratory distress syndrome (ARDS) as per Berlin definition \[[@CR37]\] when admitted at general wards (all *P* \> 0.09; Table [3](#Tab3){ref-type="table"}); however, there was significantly higher respiratory support rate (OR 5.01, 95% CI \[1.30, 19.3\], *P* = 0.019), and this was mostly attributed to higher rate of NPPV use (OR 5.96, 95% CI \[1.57, 22.6\], *P* = 0.009; Table [4](#Tab4){ref-type="table"}). And there was significantly reduced predicted hospital discharge (HR 0.62 \[0.20, 1.87\], *P* = 0.030), indicating significantly longer LOS in SAP (Table [4](#Tab4){ref-type="table"}), while rate of persistent OF, MOF, local complications, necrosectomy, and mortality were similar (all *P* \> 0.19, Table [4](#Tab4){ref-type="table"}).Table 3Comparison of baseline parameters and ARDS level in hemoconcentrated SAP patients between different fluid ratesParametersSAP*P* value^*a*^Rate \< 3 ml/kg/h\
*n *= 29Rate ≥ 3 ml/kg/h\
*n* = 49Demographics Age, years, median (IQR)46 (41, 53)46 (38, 52)0.580 Gender, male (%)23 (79.3)36 (73.5)0.599 Body mass index (kg/m^2^), median (IQR)26.1 (23.1, 28.1)26.8 (24.2, 30.0)0.379 Charlson comorbidity index, median (IQR)1 (0--2)1 (0--2)0.496 Time to admission (h), median (IQR)24 (21--24)24 (17--24)0.438Etiology Biliary (%)12 (41.4)13 (26.5)0.213 Hypertriglyceridemia (%)8 (27.6)20 (40.9)0.329 Alcoholic (%)06 (12.2)0.079 Others (%)9 (31.0)10 (20.4)0.413Clinical scoring systems SIRS, median (IQR)3 (2--3)3 (2--3)0.486 Glasgow, median (IQR)2 (2--3)3 (2--4)0.091 APACHE II, median (IQR)8 (6--11)8 (7--14)0.685 SOFA, median (IQR)2 (0--3)2 (1--4)0.152ARDS level at admission (%) Mild (200--300)9 (33.3)9 (19.6)0.188 Moderate (100--200)6 (22.2)13 (28.3)0.570 Severe (≤ 100)02 (4.3)0.272*ARDS* acute respiratory distress syndrome, *SAP* severe acute pancreatitis, *IQR* interquartile range, *SIRS* systemic inflammatory response syndrome, *APACHE II* Acute Physiology and Chronic Health Evaluation II, *SOFA* Sequential Organ Failure Assessment^a^Indicates *χ*^2^ or Fisher's exact test for qualitative data and Mann--Whitney *U* test for quantitative dataTable 4Comparison of clinical outcomes in hemoconcentrated SAP patients between different fluid ratesClinical outcomesSAP*P* value^a^Estimate (95% CI)^b^Adjusted *P* value^c^ESFT (rate \< 3 ml/kg/h)\
*n* = 29ERFT (rate ≥ 3 ml/kg/h)\
*n* = 49Single persistent OF Respiratory (%)27 (93.1)48 (98.0)0.2813.33 (0.27, 41.5)0.350 Circulatory (%)1 (3.4)9 (18.4)0.0574.39 (0.48, 40.0)0.189 Renal (%)5 (17.2)11 (22.4)0.5820.64 (0.15, 2.81)0.556MOF (%)4 (13.8)14 (28.6)0.1341.59 (0.36, 6.99)0.542HDU/ICU admission (%)23 (79.3)43 (87.8)0.3181.89 (0.52, 6.89)0.333Respiratory support (%)^d^20 (69.0)45 (91.8)**0.009**5.01 (1.30, 19.3)**0.019** NPPV (%)18 (62.1)41 (83.7)**0.032**5.96 (1.57, 22.6)**0.009** IMV (%)6 (20.7)15 (30.6)0.3401.48 (0.43, 5.08)0.530Local complication Acute peripancreatic fluid collection (%)21 (72.4)36 (73.5)0.9190.89 (0.30, 2.64)0.832 ANC (%)13 (44.8)22 (44.9)0.9950.99 (0.37, 2.50)0.925Necrosectomy (%)6 (20.7)5 (10.2)0.1980.48 (0.13, 1.84)0.285Mortality (%)7 (24.1)10 (20.4)0.7000.29 (0.09, 0.89)0.386Hospital LOS, median (IQR)^e^17 (10-22)21 (13-29)**0.068**0.62 (0.20, 1.87)**0.030**Bold values indicate statistical significance *P* \< 0.05*SAP* severe acute pancreatitis, *CI* confidence interval, *ESFT* early slow fluid therapy, *ERFT* early rapid fluid therapy, *OF* organ failure, *MOF* multiple organ failure, *HDU* high-dependency unit, *ICU* intensive care unit, *NPPV* noninvasive positive-pressure ventilation, *IMV* invasive mechanic ventilation, *ANC* acute necrotic collection, *LOS* length of stay, *IQR* interquartile range^a^Indicates *χ*^2^ (or Fisher's exact test) for qualitative data and Mann--Whitney *U* test for quantitative data^b^Odds ratio for qualitative data and hazard ratio for quantitative data (deceased patients are considered as truncated data)^c^Indicates multivariate logistic regression model for qualitative data and Cox proportional hazards model quantitative data, respectively, after adjusting baseline variables from the univariate analysis with *P* \< 0.2^d^In ESFT group, 14 only had NPPV, 4 had NPPV and then IMV, 2 had IMV without prior NPPV; in ERFT group, 30 only had NPPV, 11 had NPPV and then IMV, 4 had IMV without prior NPPV^e^Predicted hospital discharge is used to calculate the estimate (deceased patients are considered as truncated data)

After adjusting for different baseline parameters, subsequent analyses showed that there were no differences in clinical outcomes in all severity categories of non-hemoconcentrated patients between ESFT and ERFT (Supplementary Table 4a-c; all *P* \> 0.15).

There were no significant differences in baseline parameters of SAP patients between non-hemoconcentrated and hemoconcentrated groups in ESFT or in ERFT. None of the clinical outcomes between non-hemoconcentrated and hemoconcentrated groups were significantly different following ESFT (Supplementary Table 5). Compared with non-hemoconcentrated patients, the hemoconcentrated patients were associated with prolonged predicted hospital discharge (HR 0.11 \[0.18, 0.68\], *P* = 0.017) following ERFT (Supplementary Table 6).

Fluid Therapy Rate and Volume {#Sec15}
-----------------------------

As expected and based on the definitions, there were significant differences in fluid rate between the four groups for those with and without hemoconcentration (Supplementary Fig. 3). The actual total fluid therapy volume given during the first 24 h was, as expected, significantly higher in patients with MSAP and SAP who received rapid fluid therapy (Supplementary Fig. 3b, c), but not in patients with MAP (Supplementary Fig. 3a).

Multivariate Logistic Regression Analyses and Sensitivity Analyses {#Sec16}
------------------------------------------------------------------

In the multivariate logistic regression analyses, 6 (including age, time to admission, body mass index, referral, hemoconcentration, and ERFT) of 9 independent covariables were associated with persistent OF, 1 (referral) with ANC, 4 (Charlson comorbidity index, body mass index, hemoconcentration, and ERFT) with mortality (Table [5](#Tab5){ref-type="table"}). Admission hemoconcentration and ERFT were significantly associated with persistent OF and mortality, but not ANC (Table [5](#Tab5){ref-type="table"}). Table 5Multivariate analyses for persistent organ failure, acute necrotic collection, and mortality in all patientsVariablePersistent organ failureAcute necrotic collectionMortalityEstimate*P*Estimate*P*Estimate*P*Age (years)^a^1.04 (1.01, 1.05)**0.003**1.00 (0.98, 1.01)0.6051.04 (1.00, 1.09)0.079Gender0.92 (0.58, 1.46)0.7331.04 (0.70, 1.54)0.8440.49 (0.20, 1.22)0.126Charlson comorbidity index^a^0.86 (0.73, 1.03)0.0990.97 (0.84, 1.12)0.6740.66 (0.44, 0.98)**0.039**Time to admission (h)^a^1.03 (1.01, 1.04)**0.007**0.99 (0.98, 1.01)0.3721.03 (0.99, 1.06)0.149Body mass index (kg/m^2^)^a^1.09 (1.03, 1.15)**0.002**1.04 (0.99, 1.08)0.1341.15 (1.04, 1.26)**0.005**Etiology0.88 (0.65, 1.18)0.3811.10 (0.87, 1.39)0.4250.89 (0.50, 1.59)0.691Referral3.38 (2.08, 5.51)**\< 0.001**2.26 (1.56, 3.28)**\< 0.001**3.02 (0.97, 9.41)0.057Hemoconcentration2.48 (1.63, 3.76)**\< 0.001**1.40 (0.98, 2.00)0.0613.95 (1.65, 9.48)**0.002**ERFT2.59 (1.74, 3.85)**\< 0.001**1.31 (0.90, 1.85)0.1302.39 (1.05, 5.44)**0.039**Bold values indicate statistical significance *P* \< 0.05

When restricted to patients admitted \< 24 h after symptoms onset, hemoconcentration and ERFT were significantly associated with persistent OF, and only hemoconcentration was significantly associated with ANC (Table [6](#Tab6){ref-type="table"}). Mortality was removed from analysis as only 8 deaths in 41 SAP patients.Table 6Multivariate analyses for persistent organ failure, acute necrotic collection in patients of admission \< 24 hVariablePersistent organ failureAcute necrotic collectionEstimate*P*Estimate*P*Age (years)^a^1.03 (0.99, 1.07)0.1061.00 (0.97, 2.11)0.760Gender1.50 (0.60, 3.76)0.3911.12 (0.60, 2.11)0.726Charlson comorbidity index^a^1.08 (0.79, 1.47)0.6531.19 (0.96, 1.49)0.119Time to admission (h)^a^1.12 (1.04, 1.21)**0.004**0.96 (0.90, 1.01)0.121Body mass index (kg/m^2^)^a^1.05 (0.95, 1.16)0.3281.04 (0.97, 1.13)0.275Etiology1.26 (0.74, 2.16)0.3921.43 (0.97, 2.11)0.071Referral2.03 (0.96, 4.28)0.0632.11 (1.23, 3.63)**0.007**Hemoconcentration5.74 (2.63, 12.5)**\< 0.001**1.77 (1.01, 3.09)**0.045**ERFT3.36 (1.58, 7.14)**0.002**1.44 (0.82, 2.53)0.202Bold values indicate statistical significance *P* \< 0.05

When restricted to patients admitted directly to West China Hospital, excluding those referred from other hospitals, only admission hemoconcentration and ERFT were associated with persistent OF and none of the other 9 covariables were significantly associated with ANC (Table [7](#Tab7){ref-type="table"}). Mortality was removed from analysis as only 4 deaths in 40 SAP patients.Table 7Multivariate analyses for persistent organ failure, acute necrotic collection in primarily admitted patientsVariablePersistent organ failureAcute necrotic collectionEstimate*P*Estimate*P*Age (years)^a^1.01 (0.97, 1.05)0.8360.98 (0.95, 1.01)0.286Gender0.44 (0.16, 1.22)0.1161.01 (0.50, 2.04)0.974Charlson comorbidity index^a^0.98 (0.69, 1.39)0.8981.11 (0.87, 1.41)0.418Time to admission (h)^a^1.02 (0.97, 1.06)0.4710.99 (0.96, 1.02)0.592Body mass index (kg/m^2^)^a^1.09 (0.96, 1.24)0.1771.04 (0.95, 1.13)0.419Etiology1.13 (0.59, 2.18)0.7151.31 (0.85, 2.03)0.225Hemoconcentration2.95 (1. 51, 7.54)**0.024**1.13 (0.59, 2.20)0.709ERFT3.12 (1.28, 7.58)**0.012**1.54 (0.81, 2.92)0.187Age, gender (male vs. female), Charlson comorbidity index, time to admission, body mass index, etiology (hypertriglyceridemia, biliary, alcoholic, others), transfer (yes vs. no), hemoconcentration (yes, hematocrit \> 44% vs. no, ≤ 44%), fluid rate (fast, ≥ 3 ml/kg/h vs. slow, \< 3 ml/kg/h) were included in multivariate logistic regression analysisBold values indicate statistical significance *P* \< 0.05*ERFT* early rapid fluid therapy^a^Continuous variable

Discussion {#Sec17}
==========

The key finding of this study is that hemoconcentrated SAP patients who received ERFT had an increased risk of respiratory dysfunction (requiring NPPV) and had an increased LOS. This was not found in hemoconcentrated MAP and MSAP patients. Multivariate logistic regression analyses confirmed that ERFT and hematocrit (on admission to general wards) were significantly associated with persistent OF and mortality, but not ANC. The important clinical implication from this study is that ERFT should be used with cautious and tailored to the patient's requirements in predicted SAP patients who remain hemoconcentrated after initial fluid therapy \[[@CR38]--[@CR40]\]. The unsolved challenge is how to reliably determine an individual patient's fluid requirements and how best to monitor the response to what is given \[[@CR41]\].

In this study, we defined hemoconcentration as admission hematocrit level \> 44%, based on previous studies \[[@CR28], [@CR29], [@CR31]\]. Our results show that patients with hemoconcentration at ward admission had significantly higher baseline clinical severity scores and worse clinical outcomes (persistent OF, MOF, ANC, and mortality), consistent with the published literature \[[@CR28], [@CR29], [@CR31]\]. The argument for ERFT is that hemoconcentration increases blood viscosity and flow resistance \[[@CR42]\] and that correcting this with early aggressive fluid therapy will improve organ perfusion (e.g., pancreas, lung, kidneys) and clinical outcomes of AP \[[@CR28], [@CR29]\]. Although oxygen-carrying capacity of the blood is reduced during hemodilution by fluid therapy, there are limits to the compensatory mechanisms (increased cardiac output and tissue oxygen extraction) with extreme hemodilution \[[@CR42]\]. Experimental studies have suggested that both hemoconcentration and rapid hemodilution are associated with increased severity of the underlying diseases \[[@CR43], [@CR44]\]. A randomized clinical trial has demonstrated that rapid hemodilution was associated with increased sepsis and mortality in patients with predicted SAP \[[@CR16]\]. The findings of the present study are consistent with this trial as ERFT in hemoconcentrated SAP patients was associated with a significant increased respiratory dysfunction (and need for NPPV) and LOS even after adjustment for differences in baseline clinical severity scores (including SIRS, Glasgow, Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scores). The most common OF is ARDS, and the onset of persistent OF is often early (with 60% in the first day of admission) \[[@CR2], [@CR45], [@CR46]\]. Given that ARDS is already present or is likely to occur in the majority of patients within the first 24 h, ERFT might be expected to worsen the severity of ARDS. Patients who are hypovolemic and without significant capillary leak will likely benefit from early and rapid fluid resuscitation, but by the time capillary leak has developed (which contributes to ARDS development) additional fluids will increase interstitial fluid volume (edema) and cause worsening ARDS. In West China Hospital, it is established practice to use NPPV to manage patients with early ARDS or at risk of ARDS \[[@CR34]\], and it is administered on the basis of standard criteria. In this study, it was found that there was an increased requirement for NPPV in patients receiving ERFT (compared with ESFT) even though the ARDS severity was comparable between these two groups.

By avoiding invasive ventilation in the majority of patients, NPPV can be an effective way to improve gas exchange and avoid complications associated with endotracheal intubation and mechanical ventilation in selected patients with ARDS \[[@CR47]--[@CR49]\]. It may be the most effective option for the initial treatment for all categories of ARDS secondary to AP as long as no contra-indication exists \[[@CR34]\].

In hemoconcentrated SAP patients of our study, there was no difference in severity of ARDS \[[@CR37]\] at ward admission between those receiving ERFT and ESFT. But there was a significantly higher rate of NPPV use in the ERFT group. This difference may be due to a significantly faster rate of fluid therapy during the first 6 h and/or a higher total fluid volume during 24 h in the ERFT group (Supplementary Fig. 3). The finding is consistent with studies which showed that rapid and high volume fluid therapy increases the risk of pulmonary edema and exacerbates respiratory failure in AP \[[@CR13], [@CR24]\]. Our study has several limitations. The fluid management data were collected retrospectively, and there was a lack of data for fluid given prior to admission to the general ward. The hematocrit prior to fluid therapy in ED was also not available. However, the prospective data we have collected indicate that a mean of approximately 1000 ml fluid was given in the ED prior to general ward admission. Another potential confounder in this study was that patients with hemoconcentration may not have received enough fluid, despite no difference between hemoconcentrated and non-hemoconcentrated patients in regard to time to admission and volume of fluid given. Hemoconcentrated patients had more severe disease and were therefore at greater risk of respiratory dysfunction such that ERFT may be just an association and not a cause. With this study design, it is not possible to absolutely prove that ERFT caused an increased requirement of NPPV. Lastly, this was a single-center cohort composed by high proportion of patients with a hyperlipidemia as etiology of AP \[[@CR2], [@CR35], [@CR36]\], which may limit the generalizability of our findings.

In conclusion, this study has shown that ERFT in hemoconcentrated patients with SAP patients is associated with increased use of NPPV and longer LOS. This was not the case in hemoconcentrated patients with MAP and MSAP or in non-hemoconcentrated patients in all three grades of severity. Because of the risks identified in this study, a better understanding of why ERFT is associated with worse clinical outcomes in hemoconcentrated patients with SAP is important. Appropriately designed randomized clinical trials are urgently needed to determine how fluid therapy should be given in patients with predicted severe disease and hemoconcentration.
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